Ann: GBM Agile Update, page-177

From the company NR the phase II was for newly diagnosed patients:

Final Phase II Glioblastoma Data Presented at SNOFinal data from a completed phase II study of paxalisib monotherapy for newly diagnosed glioblastoma patients with unmethylated MGMT promotor status (NCT03522298), sponsored by Kazia Therapeutics, was presented at the annual meeting of the Society for Neuro-Oncology (SNO), held in Tampa, FL, from 17-20 November 2022.Just trying to understand these latest posts.


Under the GBM study, per the registration site, the trial covers both newly and recurrent GBM.

We just need the results now and see if it is consistent with Phase II -15 month OS.